Comment le bénéfice par action récent de OMER se compare-t-il aux attentes ?
Comment les revenus de Omeros Corp OMER se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour Omeros Corp ?
Quel est le score de qualité des bénéfices pour Omeros Corp ?
Quand Omeros Corp publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de Omeros Corp ?
Omeros Corp a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
$12.01
Prix d'ouverture
$11.65
Plage de la journée
$11.52 - $12.46
Plage de 52 semaines
$2.95 - $17.65
Volume
1.7M
Volume moyen
3.6M
BPA (TTM)
-2.18
Rendement en dividend
--
Capitalisation boursière
$872.7M
Qu’est-ce que OMER ?
Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 202 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The firm's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The firm also has preclinical programs, including an oncology platform for the development of novel therapeutics.